This post was originally published on this site
ZURICH (Reuters) – Lonza is investing in new drug product manufacturing capacity at its site in Guangzhou, China, the Swiss company said on Monday.
The sterile, multi-product fill and finish line is expected to be completed in 2022 and will create more than 150 jobs. Lonza, which has been making ingredients for Moderna (NASDAQ:MRNA)’s COVID-19 vaccine, did not say how much it was spending on the Guangzhou plant.
